Aoxing Pharmaceutical Company, Inc.
AOXG · OTC
6/30/2025 | 6/30/2024 | |
|---|---|---|
| Valuation | ||
| PEG Ratio | -0.16 | 0.00 |
| FCF Yield | 0.00% | -0.99% |
| EV / EBITDA | 0.00 | 0.00 |
| Quality | ||
| ROIC | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | – |
| Growth | ||
| Revenue 3-Year CAGR | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% |
| Safety | ||
| Net Debt / EBITDA | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 |
| Efficiency | ||
| Inventory Turnover | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 |